Broadcom (AVGO) call put ratio 1.4 calls to 1 put into quarter results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/20/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
Broadcom Limited (AVGO) PT Raised to $295 at Truist Securities, 'Buy the near-term weakness'
June 6, 2025 7:06 AM EDTTruist Securities analyst William Stein raised the price target on Broadcom Limited (NASDAQ: AVGO) to $295.00 (from $267.00) while maintaining a Buy rating.
The analyst comments "Buy the near-term weakness. AVGO posted very modest upside to CQ1 (Apr) results, and CQ2 (July) guidance.... More
Broadcom Limited (AVGO) PT Raised to $325 at JPMorgan
June 6, 2025 5:16 AM EDTJPMorgan analyst Harlan Sur raised the price target on Broadcom Limited (NASDAQ: AVGO) to $325.00 (from $250.00) while maintaining a Overweight rating.
The analyst comments "We see the recent ruling from the U.S. District Court for the District of Delaware in favor of ACAD regarding its 721 formulation patent for Nuplazid (pimavanserin) on both infringement and validity arguments against Aurobindo Pharma and other ANDA filers (see document here) as a clear positive. Note that the 721 patent provides protection for the Nuplazid 34mg capsule formulation into 2038. We believe it is logical to assume the parties... More
Broadcom Limited (AVGO) PT Raised to $304 at Evercore ISI, 'We’re Still Buyers'
June 6, 2025 4:54 AM EDTEvercore ISI analyst Mark Lipacis raised the price target on Broadcom Limited (NASDAQ: AVGO) to $304.00 (from $267.00) while maintaining a Outperform rating.
The analyst comments "Were Still Buyers of AVGO after an in-line AprQ print and implied EPS outlook that is $0.01 below consensus. AI revs... More
Broadcom Limited (AVGO) PT Raised to $315 at KeyBanc
June 6, 2025 4:49 AM EDTKeyBanc analyst John Vinh raised the price target on Broadcom Limited (NASDAQ: AVGO) to $315.00 (from $275.00) while maintaining a Overweight rating.
The analyst comments "AVGO reported solid F2Q (Apr) results and provided mixed F3Q (Jul) guidance (higher revs, lower... More
